|Bid||55.17 x 1000|
|Ask||55.50 x 3200|
|Day's Range||54.64 - 55.21|
|52 Week Range||46.93 - 58.10|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||19.79|
|Forward Dividend & Yield||1.80 (3.45%)|
|Ex-Dividend Date||May 04, 2022|
|1y Target Est||64.13|
Over the past six months, the market has fallen sharply thanks to a toxic combination of fears about a looming recession, rising inflation, and rising interest rates. Growth stocks and unprofitable companies have been especially hard hit. Sanofi (NASDAQ: SNY) is a multinational pharma giant with a market cap in excess of $135 billion, and its shares are up by over 17% from six months ago.
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.